Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 226915
                    [Title] => Experts debate first-line therapy for heart failure
                    [Summary] => Results of new clinical trials are reinforcing the role of the angiotensin receptor blockers (ARBs) in the treatment of patients with heart failure (HF). 


Previously, the angiotensin converting enzyme inhibitors (ACEi) were considered as first-line drug in HF patients. Now, heart experts are debating if ARBs can also be considered as another first-line drug to be given with ACEi or to replace it altogether in those who cannot tolerate ACEi due to side-effects, which can be as many as 35 percent of HF patients. 


                    [DatePublished] => 2003-11-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 225185
                    [Title] => Study shows hope for heart failure patients
                    [Summary] => Patients with heart failure still carry a high rate of death and re-hospitalization. There is still a big need to come up with new therapies which can significantly optimize treatment of patients suffering from heart failure. 


Angiotensin receptor blockers (ARB), a class of drugs popularly prescribed for high blood pressure, are filling in this need. 


                    [DatePublished] => 2003-10-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

DR. MAY DONATO-TAN

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 226915
                    [Title] => Experts debate first-line therapy for heart failure
                    [Summary] => Results of new clinical trials are reinforcing the role of the angiotensin receptor blockers (ARBs) in the treatment of patients with heart failure (HF). 


Previously, the angiotensin converting enzyme inhibitors (ACEi) were considered as first-line drug in HF patients. Now, heart experts are debating if ARBs can also be considered as another first-line drug to be given with ACEi or to replace it altogether in those who cannot tolerate ACEi due to side-effects, which can be as many as 35 percent of HF patients. 


                    [DatePublished] => 2003-11-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 225185
                    [Title] => Study shows hope for heart failure patients
                    [Summary] => Patients with heart failure still carry a high rate of death and re-hospitalization. There is still a big need to come up with new therapies which can significantly optimize treatment of patients suffering from heart failure. 


Angiotensin receptor blockers (ARB), a class of drugs popularly prescribed for high blood pressure, are filling in this need. 


                    [DatePublished] => 2003-10-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Experts debate first-line therapy for heart failure

November 6, 2003 - 12:00am

Results of new clinical trials are reinforcing the role of the angiotensin receptor blockers (ARBs) in the treatment of patients with heart failure (HF). Previously, the angiotensin converting enzyme inhibitors...

Science and Environment

Study shows hope for heart failure patients

October 23, 2003 - 12:00am

Patients with heart failure still carry a high rate of death and re-hospitalization. There is still a big need to come up with new therapies which can significantly optimize treatment of patients suffering from heart...

Science and Environment